Rösche J, Pohley I, Rantsch K, Walter U, Benecke R
Klinik und Poliklinik für Neurologie, Universität Rostock.
Fortschr Neurol Psychiatr. 2013 Jan;81(1):21-7. doi: 10.1055/s-0032-1312951. Epub 2012 Aug 13.
Non-convulsive status epilepticus and epilepsia partialis continua are common epileptic conditions for which straightforward recommendations based on controlled randomised trials for treatment of therapy refractory courses are lacking. Therefore in these conditions sometimes antiepileptic drugs that are not approved by governmental authorities for the treatment of status epilepticus (SE) are used. Here we review all case reports and case series concerning the treatment of SE with levetiracetam (LEV), that had been listed in pub-med up to December 12th 2011. Additionally we analysed abstracts and papers in peer reviewed journals, that were listed in the references of the primarily reviewed papers. Furthermore we looked for LEV treatments in papers on the use of lacosamide (LCM) in SE. LEV was given in dosages ranging from 500 mg to 9000 mg per day. Side effects were especially sedation and irritability. Estimated on the basis of the case series the overall success-rate of LEV in terminating status epilepticus may be set in a range between 53.7% and 58.1%. Therefore LEV may be a useful alternative for the treatment of SE when the approved drugs are contraindicated or when these drugs have been taken without success.
非惊厥性癫痫持续状态和部分性癫痫持续状态是常见的癫痫病症，目前缺乏基于对照随机试验针对治疗难治性病程的直接建议。因此，在这些情况下，有时会使用未经政府当局批准用于治疗癫痫持续状态（SE）的抗癫痫药物。在此，我们回顾了截至2011年12月12日在PubMed上列出的所有关于用左乙拉西坦（LEV）治疗SE的病例报告和病例系列。此外，我们分析了同行评审期刊中的摘要和论文，这些摘要和论文列于主要综述论文的参考文献中。此外，我们在关于拉科酰胺（LCM）用于SE治疗的论文中查找LEV治疗情况。LEV的给药剂量为每天500毫克至9000毫克。副作用主要是镇静和易怒。根据病例系列估计，LEV终止癫痫持续状态的总体成功率可能在53.7%至58.1%之间。因此，当批准的药物禁忌或使用这些药物未成功时，LEV可能是治疗SE的一种有用替代药物。
